Concord Wealth Partners Acquires 1,044 Shares of Humana Inc. (NYSE:HUM)

Concord Wealth Partners lifted its holdings in shares of Humana Inc. (NYSE:HUM) by 4,539.1% in the 4th quarter, Holdings Channel reports. The institutional investor owned 1,067 shares of the insurance provider’s stock after acquiring an additional 1,044 shares during the period. Concord Wealth Partners’ holdings in Humana were worth $271,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Concord Asset Management LLC VA bought a new position in Humana in the fourth quarter valued at approximately $266,000. Factory Mutual Insurance Co. acquired a new position in shares of Humana in the 4th quarter valued at $5,480,000. SOL Capital Management CO boosted its position in shares of Humana by 89.7% in the 4th quarter. SOL Capital Management CO now owns 12,300 shares of the insurance provider’s stock worth $3,121,000 after purchasing an additional 5,817 shares during the last quarter. Sivik Global Healthcare LLC grew its stake in shares of Humana by 100.0% during the fourth quarter. Sivik Global Healthcare LLC now owns 20,000 shares of the insurance provider’s stock worth $5,074,000 after purchasing an additional 10,000 shares during the period. Finally, OLD National Bancorp IN increased its holdings in Humana by 7.0% in the fourth quarter. OLD National Bancorp IN now owns 2,797 shares of the insurance provider’s stock valued at $710,000 after purchasing an additional 184 shares during the last quarter. 92.38% of the stock is owned by institutional investors.

Humana Stock Down 1.2 %

Humana stock opened at $293.40 on Friday. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.67. Humana Inc. has a 1-year low of $213.31 and a 1-year high of $406.46. The company has a fifty day simple moving average of $275.36 and a 200 day simple moving average of $302.40. The company has a market cap of $35.33 billion, a P/E ratio of 25.99, a price-to-earnings-growth ratio of 2.22 and a beta of 0.55.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share for the quarter, beating the consensus estimate of $3.48 by $0.68. Humana had a return on equity of 13.20% and a net margin of 1.18%. The company had revenue of $29.30 billion during the quarter, compared to analysts’ expectations of $28.66 billion. Research analysts anticipate that Humana Inc. will post 16.11 earnings per share for the current fiscal year.

Insider Activity at Humana

In other news, insider Timothy S. Huval sold 3,703 shares of the company’s stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total transaction of $948,930.78. Following the sale, the insider now owns 8,181 shares in the company, valued at $2,096,463.06. This represents a 31.16 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Insiders own 0.32% of the company’s stock.

Analysts Set New Price Targets

HUM has been the topic of a number of recent analyst reports. Wells Fargo & Company reduced their target price on Humana from $387.00 to $290.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. Jefferies Financial Group lowered shares of Humana from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $519.00 to $253.00 in a research note on Monday, October 7th. TD Cowen upped their target price on shares of Humana from $261.00 to $268.00 and gave the company a “hold” rating in a research note on Monday, November 4th. KeyCorp initiated coverage on shares of Humana in a research report on Friday, October 11th. They set a “sector weight” rating on the stock. Finally, Piper Sandler upped their price objective on shares of Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research report on Wednesday, January 15th. Nineteen research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, Humana presently has a consensus rating of “Hold” and an average price target of $297.68.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.